PMID- 24667368
OWN - NLM
STAT- MEDLINE
DCOM- 20141228
LR  - 20151119
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 20
IP  - 1
DP  - 2014 May
TI  - Protocatechuic acid improves cognitive deficits and attenuates amyloid deposits, 
      inflammatory response in aged AbetaPP/PS1 double transgenic mice.
PG  - 276-81
LID - S1567-5769(14)00105-2 [pii]
LID - 10.1016/j.intimp.2014.03.006 [doi]
AB  - Protocatechuic acid (PCA), a phenolic compound of Radix Salviae Miltiorrhizae 
      (RSM), has been found to have a protective effect on improving cognitive deficits 
      in STZ-induced AD rats. The present study aimed to evaluate the potential 
      protection activity of PCA on improving cognitive deficits and attenuating Abeta 
      deposition and inflammatory responses in aged AbetaPP/PS1 double transgenic AD-model 
      mice. The results of Morris water maze test showed that PCA (100mg/kg) 
      significantly prolonged the mean latency time and the path length of AbetaPP/PS1 
      mice. PCA could significantly reduce the number of Abeta positive expressions in the 
      hippocampus and cerebral cortex of AbetaPP/PS1 mice by immunocytochemical assay with 
      Congo red staining and decrease remarkably APP expression level by Western blot 
      analysis (P<0.01). The results from ELISA and Western blot analysis showed that 
      the levels of inflammatory cytokines including TNF-alpha, IL-1beta, IL-6 and IL-8 
      decreased remarkably by the treatment with PCA (P<0.01). Further, there was a 
      substantial increase of brain derived neurotrophic factor (BDNF) in the 
      hippocampus and cerebral cortex of AbetaPP/PS1 mice treated with PCA (P<0.01). The 
      present study provided confirmatory evidence that PCA significantly decreased Abeta 
      deposits, APP and inflammatory response, whereas increased learning and memory 
      ability, as well as enhanced BDNF level. Our findings indicated that PCA is an 
      effective neuroprotective agent for AD therapy. It might be associated with the 
      attenuation on Abeta deposits and inflammation responses involved in the process.
CI  - Copyright (c) 2014 Elsevier B.V. All rights reserved.
FAU - Song, Yu
AU  - Song Y
AD  - School of Pharmacy, Xinxiang Medical University, Xinxiang 453003, Henan Province, 
      People's Republic of China.
FAU - Cui, Taizhen
AU  - Cui T
AD  - School of Pharmacy, Xinxiang Medical University, Xinxiang 453003, Henan Province, 
      People's Republic of China.
FAU - Xie, Na
AU  - Xie N
AD  - The Cardiology Department of the Third Af fi liated Hospital of Xinxiang Medical 
      University, Xinxiang 453003, Henan Province, People's Republic of China.
FAU - Zhang, Xiaoyi
AU  - Zhang X
AD  - School of Pharmacy, Xinxiang Medical University, Xinxiang 453003, Henan Province, 
      People's Republic of China.
FAU - Qian, Zhibin
AU  - Qian Z
AD  - The Cardiology Department of the Third Af fi liated Hospital of Xinxiang Medical 
      University, Xinxiang 453003, Henan Province, People's Republic of China.
FAU - Liu, Juyuan
AU  - Liu J
AD  - School of Pharmacy, Xinxiang Medical University, Xinxiang 453003, Henan Province, 
      People's Republic of China. Electronic address: yaolixue2010@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140322
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Amyloid beta-Protein Precursor)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Cytokines)
RN  - 0 (Hydroxybenzoates)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Presenilin-1)
RN  - 0 (presenilin 1, mouse)
RN  - 36R5QJ8L4B (protocatechuic acid)
SB  - IM
MH  - Alzheimer Disease/*drug therapy/metabolism
MH  - Amyloid beta-Peptides/metabolism
MH  - Amyloid beta-Protein Precursor/genetics/metabolism
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/metabolism
MH  - Cerebral Cortex/drug effects/metabolism
MH  - Cytokines/metabolism
MH  - Hippocampus/drug effects/metabolism
MH  - Hydroxybenzoates/pharmacology/*therapeutic use
MH  - Male
MH  - Maze Learning/drug effects
MH  - Memory/drug effects
MH  - Mice, Transgenic
MH  - Neuroprotective Agents/pharmacology/*therapeutic use
MH  - Presenilin-1/genetics
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Amyloid-beta
OT  - Cognitive deficits
OT  - Inflammation
OT  - Protocatechuic acid
EDAT- 2014/03/29 06:00
MHDA- 2014/12/30 06:00
CRDT- 2014/03/27 06:00
PHST- 2014/01/30 00:00 [received]
PHST- 2014/02/22 00:00 [revised]
PHST- 2014/03/05 00:00 [accepted]
PHST- 2014/03/27 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2014/12/30 06:00 [medline]
AID - S1567-5769(14)00105-2 [pii]
AID - 10.1016/j.intimp.2014.03.006 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2014 May;20(1):276-81. doi: 10.1016/j.intimp.2014.03.006. 
      Epub 2014 Mar 22.